Replies to post #201094 on Biotech Values

[DewDiligence]

…if IPR can reduce lawsuits, then its generally good for bios.

If the USSC retains the right to initiate an IPR to challenge a US patent, it will be somewhat bearish for biotech companies in general, but bullish for FoB companies such as MNTA.